Bayer's Finerenone Marches Ahead; Is Phase III A Hill Too Steep?
This article was originally published in Scrip
Executive Summary
Bayer AG's Phase III program for its heart failure drug finerenone could create a dual indication product with a strong label, but those potential rewards carry their own risks, since it is uncertain if the design can adequately address appropriate dosing, the crucial hyperkalemia safety factor, and accommodation of Novartis AG's just-approved Entresto (sacubitril/valsartan).
You may also be interested in...
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.
Can-Fite Plans Phase III For Namodenoson, Despite Liver Cancer Trial Failure
Patients with the most severe type of disease were all randomized to treatment with the study drug, which may have had a negative impact on outcome, the Israeli company suggested.